Skip to main content
Terug
PROK logo

ProKidney Corp.

Datakwaliteit: 100%
PROK
NASDAQ Healthcare Biotechnology
€ 1,94
▲ € 0,01 (0,52%)
Marktkapitalisatie: 561,66M
Dagbereik
€ 1,86 € 2,00
52-Weeksbereik
€ 0,46 € 7,13
Volume
804.092
50D / 200D Gem.
€ 2,16 / € 2,35
Vorige Slotkoers
€ 1,93

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (626 peers)

Metriek Aandeel Sector Mediaan
P/E -3,7 0,4
P/B 1,9 2,9
ROE % 3,8
Net Margin % -16977,8 3,9
Rev Growth 5Y % 10,0
D/E 0,0 0,2

Koersdoel Analisten

Hold
€ 4,67 +140.7%
Low: € 3,00 High: € 6,00
Forward WPA
-€ 0,71
Omzet Sch.
300000

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2030 € 0,11
€ 0,11 – € 0,11
330 M 1
FY2029 -€ 0,26
-€ 0,26 – -€ 0,26
130 M 1
FY2028 -€ 0,39
-€ 0,44 – -€ 0,33
60 M 2

Belangrijkste Punten

Debt/Equity of 0,01 — conservative balance sheet
Negative free cash flow of -135,31M
PEG of 0,11 suggests growth is underpriced
Capital intensive — 1701,68% of revenue goes to capex

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)1075,00%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
N/A
ROIC-40,74%
Net Margin-16977,83%
Op. Margin-18477,83%

Veiligheid

Debt / Equity
0,01
Current Ratio9,13
Interest Coverage-41251,75

Waardering

P/E Ratio
-3,70
P/B Ratio1,87
EV/EBITDAN/A
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 1075,00% Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 893.000,0 Net Income (TTM) -151,61M
ROE N/A ROA -45,18%
Gross Margin -540,76% Operating Margin -18477,83%
Net Margin -16977,83% Free Cash Flow (TTM) -135,31M
ROIC -40,74% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,01 Current Ratio 9,13
Interest Coverage -41251,75 Dividend Yield 0,00%
Valuation
P/E Ratio -3,70 P/B Ratio 1,87
P/S Ratio 628,96 PEG Ratio 0,11
EV/EBITDA N/A Dividend Yield 0,00%
Market Cap 561,66M Enterprise Value 456,09M

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 893.000,0 76.000,0 0,0 0,0 0,0
Net Income -151,61M -61,19M -35,47M -108,03M -55,15M
EPS (Diluted) -0,51 -0,62 -0,57 -1,76 -1,73
Gross Profit -4,83M 76.000,0 0,0 0,0 0,0
Operating Income -165,01M -183,68M -151,52M -153,01M -55,11M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 335,57M 441,07M 420,55M 518,00M 40,30M
Total Liabilities 34,78M 39,44M 29,22M 13,06M 13,38M
Shareholders' Equity 300,79M -994,95M -1,10B -1,10B 26,92M
Total Debt 2,97M 3,24M 4,41M 2,40M 1,33M
Cash & Equivalents 108,54M 99,12M 60,65M 490,25M 20,56M
Current Assets 280,68M 395,88M 374,15M 504,72M 27,27M
Current Liabilities 30,74M 36,22M 25,04M 10,87M 12,31M